抗GD2抗体用于骨肉瘤放射性药物成像
本研究评估人源化抗GD2抗体hu3F8作为靶向放射性药物成像载体,用于人及犬骨肉瘤(OS)。hu3F8与人和犬OS细胞及犬OS肿瘤交叉反应且亲和力高,[111In]In-hu3F8在荷瘤小鼠中选择性摄取于肿瘤组织,在自发OS犬的SPECT/CT成像中所有转移灶均见明显摄取,免疫组化证实放射性标记hu3F8在骨及软组织病灶内广泛结合。结论表明基于hu3F8的放射性药物成像靶向OS细胞及自发犬OS肿瘤的GD2具有可行性,支持其用于OS精准成像及未来放射性药物治疗的潜力。
要点
- hu3F8与人和犬OS细胞及犬OS肿瘤交叉反应,结合亲和力高。
- [111In]In-hu3F8在荷瘤小鼠肿瘤组织中选择性摄取,自发OS犬所有转移灶SPECT/CT均见明显摄取。
- 免疫组化证实放射性标记hu3F8在骨及软组织病灶内广泛结合。
核心结论
- 本研究证明使用基于hu3F8的放射性药物成像靶向OS细胞及自发犬OS肿瘤上的GD2具有可行性。
- hu3F8能够以靶向方式递送成像有效载荷,支持其用于OS精准成像及未来放射性药物治疗的潜在用途。
研究设计与样本
- 研究通过免疫组化和流式细胞术检测hu3F8与人和犬OS细胞及肿瘤的交叉反应性。
- 将hu3F8用铟-111放射性标记,在荷瘤小鼠中评估[111In]In-hu3F8的生物分布。
- 在自发OS犬中测试[111In]In-hu3F8对转移性OS的靶向能力。
主要发现
- hu3F8与人和犬OS细胞及犬OS肿瘤交叉反应,结合亲和力高。
- 生物分布研究显示[111In]In-hu3F8在肿瘤组织中选择性摄取。
- 自发OS犬的SPECT/CT成像显示[111In]In-hu3F8在所有转移灶中明显摄取。
- 免疫组化证实放射性标记hu3F8在骨及软组织病灶内广泛结合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Osteosarcoma (OS) is the most frequently diagnosed bone cancer in children with little improvement in overall survival in the past decades. The high surface expression of disialoganglioside GD2 on OS tumors and restricted expression in normal tissues makes it an ideal target for anti-OS radiopharmaceuticals. Since human and canine OS share many biological and molecular features, spontaneously occurring OS in canines has been an ideal model for testing new imaging and treatment modalities for human translation. In this study, we evaluated a humanized anti-GD2 antibody, hu3F8, as a potential delivery vector for targeted radiopharmaceutical imaging of human and canine OS. METHODS: The cross-reactivity of hu3F8 with human and canine OS cells and tumors was examined by immunohistochemistry and flow cytometry. The hu3F8 was radiolabeled with indium-111, and the biodistribution of [111In]In-hu3F8 was assessed in tumor xenograft-bearing mice. The targeting ability of [111In]In-hu3F8 to metastatic OS was tested in spontaneous OS canines. RESULTS: The hu3F8 cross reacts with human and canine OS cells and canine OS tumors with high binding affinity. Biodistribution studies revealed selective uptake of [111In]In-hu3F8 in tumor tissue. SPECT/CT imaging of spontaneous OS canines demonstrated avid uptake of [111In]In-hu3F8 in all metastatic lesions. Immunohistochemistry confirmed the extensive binding of radiolabeled hu3F8 within both osseous and soft lesions. CONCLUSION: This study demonstrates the feasibility of targeting GD2 on OS cells and spontaneous OS canine tumors using hu3F8-based radiopharmaceutical imaging. Its ability to deliver an imaging payload in a targeted manner supports the utility of hu3F8 for precision imaging of OS and potential future use in radiopharmaceutical therapy.
引用
- Fu Y, Yu J, Liatsou I, et al. Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma. Eur J Nucl Med Mol Imaging. 2022. PMID: 35809088. doi:10.1007/s00259-022-05888-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。